NERV — Minerva Neurosciences Income Statement
0.000.00%
- $21.96m
- -$12.86m
Annual income statement for Minerva Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 41.2 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 75.9 | 39.3 | 45.4 | 25.2 | 23.1 |
Operating Profit | -75.9 | 1.85 | -45.4 | -25.2 | -23.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -74.4 | 1.94 | -51.7 | -32.1 | -30 |
Provision for Income Taxes | |||||
Net Income After Taxes | -72.2 | 1.94 | -49.9 | -32.1 | -30 |
Net Income Before Extraordinary Items | |||||
Net Income | -72.2 | 1.94 | -49.9 | -32.1 | -30 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -72.2 | 1.94 | -49.9 | -32.1 | -30 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -14.8 | 0.379 | -9.35 | -6.01 | -4.61 |